USA > JAPAN based Otsuka Pharmaceutical is set to acquire USA based Visterra for approximately $430 million

otsuka logo In an all cash transaction, Japan based Otsuka Pharmaceutical is set to acquire USA based Visterra Inc. for approximately $430 million. The transaction has been approved by boards of directors of both companies and the deal is subject to customary closing conditions, including expiration or termination of the waiting period under U.S. antitrust laws and is expected to close in More …

USA > UK based Eli Lilly is set to acquire USA based ARMO BioSciences for $1.6 billion

Eli Lilly logo For $50 per share or approximate value of $1.6 billion, UK based Eli Lilly is all set to acquire USA based ARMO BioSciences. ARMO BioSciences is a company that is working on a late stage immune oncology that is developing a pipeline of novel, proprietary product candidates that is designed to activate the immune system of cancer patients to recognize More …

USA > Switzerland based Novartis is set to acquire USA based AveXis Inc. for $8.7 billion

Novartis logo To transform care in SMA and expand its position as a gene therapy and Neuroscience leader, Novartis is set to acquire AveXis Inc. for $8.7 billion. AVXS-101, AveXis lead product candidate, has the potential to be the first ever one time gene replacement therapy for spinal muscular atrophy (SMA). SMA is a disease that results in either early death or More …

​CANADA > France based Sanofi is set to invest €350 million($433.18 million) in Canadian vaccine facility

Sanofi logo For the construction of a new state of the art vaccine manufacturing facility, Sanofi is investing €350 million($433.18 million) at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario, Canada. Demonstrating Sanofi’s commitment to innovation and leadership in global public health, the investment bolsters Sanofi’s Canada operations. The new investment is the largest ever investment by Sanofi in a single building More …

SWITZERLAND > UK based GSK (GlaxoSmithKline) is set to buyout Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion

gsk logo UK based GSK is all set to buyout Switzerland based Novartis stake in the Consumer Healthcare Joint venture for $13 billion. Formed as part of the three part transaction between GSK and Novartis in 2014, Consumer Healthcare Joint Venture’s 100% ownership by GSK enables GSK shareholders to capture full value of future performance. According to Emma Walmsley, Chief Executive Officer, More …

IRELAND > South Korea based SK Biotek acquires Bristol-Myers Squibb API  Swords manufacturing facility in  Dublin, Ireland

SK biotek logo Becoming the first South Korean pharmaceuticals company to invest in Ireland, SK Biotech acquires Dublin based Bristol- Myers Squibb API. SK biotek is owned by SK Group and is a global life sciences company. The acquisition was completed by the end of 2017 and 360 employees of Swords Campus have transitioned to SK biotek employment for 1st January 2018. SK More …

SWITZERLAND > India based Glenmark Pharmaceuticals is set to establish a new discovery center at Biopôle campus in Lausanne, Switzerland

glenmark logo To enhance its translational research capabilities, Glenmark Pharmaceuticals is set to open a new discovery center at the Biopôle campus in Lausanne, Switzerland. Glenmark Pharmaceuticals entered the Swiss market in 2004 and currently, Glenmark Pharmaceuticals employs around 160 people in its R&D center for biologics in the canton of Neuchâtel Glenmark will continue to invest in its existing Swiss site and More …

NEPAL > India based Tizig Pharma is set to invest Rs 351 million ($3.4 million) in cancer drug plant in Bhaktapur, Nepal

Tizig Pharma Pvt. Ltd. is set to invest Rs 351 million ($3.4 million) in Nepal for cancer drug production plant. As the cancer patients have increased in recent years, the India based company is set to invest in Nepal. Venkatesham Ambati, an Indian citizen, is the sole investor of the project. According to Khagendra Basnet, Director of the Department of More …